| Marinus Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics to treat patients suffering from rare seizure disorders. Co.'s clinical stage product candidate, ganaxolone, is a positive allosteric modulator of gamma-aminobutyric acid (GABAA) being developed in formulations for two different routes of administration: intravenous (IV) and oral. Ganaxolone is a synthetic analog of allopregnanolone, an endogenous neurosteroid. Ganaxolone acts at both synaptic and extrasynaptic GABAA receptors and exhibits anti-seizure, antidepressant and anxiolytic properties. We show 30 historical shares outstanding datapoints in our coverage of MRNS's shares outstanding history.|
Understanding the changing numbers of MRNS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MRNS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MRNS by allowing them to research MRNS shares outstanding history
as well as any other stock in our coverage universe.